Abstracts tagged "Mouse model"

Abstract Number: 2859 • 2013 ACR/ARHP Annual Meeting
Pain Pathway Activation In Dorsal Root Ganglia and Dorsal Horn In a Murine Surgical Model Of Osteoarthritis
Rachel E. Miller¹, Phuong Tran², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose: Using a surgical mouse model of osteoarthritis (OA), destabilization of the medial meniscus (DMM), we monitor pain and associated pathways over a period of…
Abstract Number: 2733 • 2013 ACR/ARHP Annual Meeting
Spontaneous Osteoarthritis In Mice By Genetic Deletion Of Nfatc1 and Nfatc2
Susan Y. Ritter¹, Matthew B. Greenblatt², Kelly Tsang¹, Dorothy Z. Hu³, John Wright⁴ and Antonios O. Aliprantis¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Pathology, Brigham and Women's Hospital, Boston, MA, ³Endocrine Unit, Massachusetts General Hospital, Boston, MA, ⁴Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Osteoarthritis (OA) was once viewed as a mechanical disease of “wear and tear”, but recent advances suggest that OA results from active dysregulation of…
Abstract Number: 2706 • 2013 ACR/ARHP Annual Meeting
Fli1 Haploinsufficiency Exacerbates Dermal Fibrosis Via Activation Of Fibroblasts, Endothelial Cells and Macrophages In Bleomycin-Treated Mice
Takashi Taniguchi¹, Yoshihide Asano¹, Kaname Akamata¹, Shinji Noda¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Maria Trojanowska² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disorder with clinical manifestations resulting from immune activation, vascular injuries and fibrosis development. Previous reports suggest that…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 2232 • 2013 ACR/ARHP Annual Meeting
Neutralization of Angiopoietin-2 Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone
Brian Naiman, Sean Turman, William Iverson, Ronald Herbst, Tomas Mustelin and Jane Connor, Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: It has recently been established that >75% of patients on methotrexate and a biologic do not achieve complete remission based on the new definition…
Abstract Number: 1284 • 2013 ACR/ARHP Annual Meeting
Nuclear Receptor 4A2 Is Differentially Expressed In Animal Models Of RA During Inflammation and Resolution
Jordan Everett¹, Fiona E. McCann², Andrew C. Palfreeman², Anita T. Shaw³, Ellen M. Gravallese⁴ and Kimberlee S. Mix¹, ¹Biological Sciences, Loyola University New Orleans, New Orleans, LA, ²NDORMS, The Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ³Division of Rheumatology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Nuclear receptor 4A2 (NR4A2 / nuclear receptor related 1 / Nurr1) is a constitutively active transcription factor with diverse roles in normal physiology and…
Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].